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1202-l 46 impact of Insulin Resistance and Hyperinsulin 
Response on Arterial Stiffness 
Toshihide Hinoi, Hrdeo Sasaki, Chikako lto, Hiroshima A-Bomb Casualty, Hiroshrma, 
Japan 
Background-Cardiovascular disease is the most common cause of disability and death 
among subjects with type 2 diabetes mellitus (DM). Measurement of pulse wave velocity 
(PWV) is a non-invasive method to estimate arterial stiffness. In order to determine the 
effect of diabetes on arterial stiffness, we conducted a large scale and cross-sectional 
study in single center. 
Methods- A total of 11,602 subjects were performed 75g-oral glucose tolerance test 
(OGTT), blood chemistry and PWV measurement, and were enrolled in the present study 
(mean age 64.5+/-8.9 years, 14% hypertension, 56% dyslipidaemia, 37% current 
smoker). We diagnosed, 5,593 were normal, 641 impaired fasting glucose (IFG), 3,360 
impaired glucose tolerance (IGT), and 2,236 Type 2 DM. 
RESULTS-Compared with normal group, abnormal groups (IFG, IGT and type 2 DM) 
had signiftcantly increased PWV(6.4 versus 6.7, 6.9 and 9.lmIsec .p<O.OOl). Multivariate 
analysis showed that age, gender male, systolic blood pressure, serum triglycerides, 2 
hour plasma glucose. and sigma-IRI (sum of insulin yalue in OGTT) were positively cor- 
related with PWV, and lower serum HDL-cholesterol was inversely correlated (all 
P<O.OOl). Linear relationship was appreciated between sigma-IRI and PWV( r=0.966, 
p=o.o14 ). 
CONCLUSION-These results suggest that, in addition to age, sex, systolic blood pres- 
sure and triglycerides, hyper-insulin response as assessed by OGTT is independently 
associated with early atherosclerosis in newly diagnosed type 2 DM. 
1202-l 47 Persistence of Impaired Vascular Function Despite an 
Improved Metabolic Profile Following Three Months of 
Significant Weight Loss 
Robert D. Brook, Robert L. Bard, Louis D’Alecy. Lynn Glazewski, Sanjay Rajagopalan, 
University of Michigan, Ann Arbor, Ml 
Background: Obesity Impairs endothelial function and arterial compliance. We therefore 
sought to determine if weight loss significantly improves vascular health. 
Methods: 43 adults (BMI 2 27 ks/ms) without other risk factors underwent a 3 month trial 
of diet + orlistat (120 mg PO QAC). Endothelial-dependent and independent vasomotion 
were determined by brachral flow-mediated dilatation (FMD) and nitroglycerin-mediated 
dilatation (NMD). Large (LVC) and small (SVC) vessel compliance was determined by 
computerized arterial pulse waveform analysis. Metabolic parameters, C-reactive protein 
(CRP), and asymmetric dimethyl arginine (ADMA) were also assessed. 
Results: Body weight was reduced by an average of 6.6 % after 3 months. BMI (34.9 * 
4.6 to 32.7 f 4.6 kg/m*. p<O.OOl) and waist circumference (107.5 * 10.7 to 102.2 * 15.4 
cm. p=O.OOl) significantly decreased. LDL-C (114 * 27 to 104 * 25 mg/dl, p=O.o05), LDL 
particle concentration (1339 f 359 to 1222 f 325 mmolll, p=O.O09), insulin (8.8 * 4.1 to 
7.4 * 2.7 UU/ml, p=O.O02), and glucose (68.3 * 6.8 to 65.5 * 9.2 mg/dl. p=O.O69) 
improved. Vascular function, CRP, and ADMA were not altered (Table). 
Conclusion: Despite reduced adiposity and a significant improvement in the metabolic 
profile, 3 months of weight reduction did not alter endothelial function or vascular compli- 
ance. These results are important because they demonstrate that a greater amount, or a 
more prolonged time period, of weight loss may be required to restore vascular health in 
overweight adults. 
Baseline Post weight loss P 
FMD (%) 3.66 * 3.54 3.74 * 3.76 0.66 
NMD (%) 17.16 * 5.69 18.67 * 7.11 0.13 
SVC ((ml/mm Hg) x 100) 10.2 * 3.6 10.5 * 5.7 0.74 
LVC ((ml/mm Hg) x 100) 16.6 zt 6.3 17.7 * 6.6 0.51 
ADMA (MM) 0.95 *0.13 0.95 * 0.15 0.75 
CRP (mg/dL) 0.47 * 0.41 0.40 * 0.45 0.23 
1202-148 C-Type Natriuretic Peptide and Adrenomedullin Levels 
in Patients With Obstructive Sleep Apnea 
Robert Walk, Anna Svatikova, Abu Shamsuzzaman, Mikolaj Winnicki. Carolyn Fieseler, 
Bruce Johnson, Virend K. Somers, Mayo Clinic, Rochester, MN 
BACKGROUND. Obstructive sleep apnea (OSA) has been related to an increased rnci- 
dence of hypertension, atherosclerosis, arterial thrombosis and other cardiovascular dis- 
eases. C-type natriuretic peptide (CNP) is a novel endothelium-derived mediator with 
vasodilatory, anti-atherogenic and anti-thrombotic properties. We hypothesized that OSA 
might be associated with reduced plasma CNP concentration. METHODS. Plasma CNP 
levels were measured during the night (at 9:30 p.m., 2 a.m., 6 a.m.) in 15 healthy male 
OSA patients and in 10 matched controls. RESULTS. Baseline CNP levels before sleep 
were significantly lower in the OSA than in the control group (21.3i2.3 vs. 32.9*4.0 pg/ 
ml, respectively, p=O.O13). During the night, there was a gradual decrease rn CNP levels 
in the control group (from 32.9k4.0 to 21.0*3.1 pglml, p=O.OlZ). However, in the OSA 
group, CNP levels increased during the period of untreated sleep apnea, and subse- 
quently decreased in response to CPAP therapy. In contrast to CNP, plasma levels of 
another endothelium-derived vasodilator, adrenomedullin, were not affected by OSA 
(either chronically or acutely). CONCLUSION. OSA exerts a twofold effect on CNP regu- 
lation. Baseline CNP production is markedly reduced, whereas acute episodes of sleep 
apnea during the night cause a modest, but significant increase in plasma CNP levels. 
1202-149 Interactive Effects of the ACE DD Polymorphism With 
the NOS Ill Homozygous G649T (Glu298-Asp) Variant in 
Determining Endothelial Function in Coronary Artery 
Disease 
Michael A. Schmidt Anjan Chakrabarti, Dana Pfeninnger, Nice Kacirotti, Claire 
Duvernoy, Anthony Killeen, Robert D. Brook, Sanjay Rajagopalan. University of 
Michigan, Ann Arbor, MI 
Background: The products of Nitric Oxide Synthase (NOS) and Angiotensin Converting 
Enzyme (ACE) play a critical role rn determining ve~~sl wall structure and function. Poly- 
morphisms in both genes have been independently demonstrated to influence propensity 
to cardiovascular events. We wished to determine the influence of the homozygous 
G649T(Gl@s + Asp) polymorphism in NOS Ill on peripheral conduit artery endothelial 
function and to elucidate the modifier role. if any, of a common ACE polymorphism. 
Methods: 397 consecutive subiects oresentina to the cardiac catheterization laboratow 
of the University of Michigan over a period of 16 months were recruited. DNA was 
extracted and PCR analvsis for ACE and NOS oolvmorohisms oerformed. Patients with 
homozygosity for G649T at both loci (TT) who belong to DD and II ACE genotype 
(groups 1 and 2) and those who are negative for this polymorphism (GG) and belong to 
either DD or II genotype (groups 3 and 4) were identified. The four groups then under- 
went determination of conduit endothelial function. Heterozygosity GIL?~* -Asp or the ID 
variant of the ACE were not studied. 
Results Median FMD value in the TT-DD group was 0.20 (-3.17, 2 01) compared to 
2.23% (-0.29.4.17) in the GG-II group. Median values in the TT-II and the GG-DD groups 
were 3.04(-1.16. 6.61) and 2.46% (-1.63. 6.52) respectively. These values were not sta- 
tistically significant (p>O.O5 by one way ANOVA). Median nitroglycerin mediated dilation 
in the four groups did not differ between the four groups (p=NS by ANOVA). Atheroscle- 
rosis burden as assessed by angiography were not different across the groups. 
Conclusions: The homozygous NOS III variant (GG) status does not seem to interact 
additively with the ACE homozygous DD genotype, in determining flow mediated vasodi- 
lation in individuals with established atherosclerosis and preexistent endothelial dys- 
function 
1202-l 50 Effect of a Severe Coronary Stenosis and Percutaneous 
Cornary Intervention on the Coronary Microcirculation 
Koen M. Maraues. Hugo J. Spruijt, Nice Westerhof, Cees A. Visser. Frans C. Visser, VU 
University Medical Center, Amsterdam, The Netherlands, ICaR-VU, Amsterdam, The 
Netherlands 
Background Classically, epicardial stenoses are thought to exert their clinical effect by 
limitation of the maximal flow capacity. In animal studies, artificial coronary stenoses 
have been shown to decrease the microvascular resistance (MR) to compensate for the 
epicardial obstruction. In human studies, data on the effect of atherosclerotic epicardial 
stenoses on the MR are conflicting. A constrictor response of the microcirculation (MC), 
supplied by a severely narrowed epicardial coronary, was found to pacing induced tachy- 
cardia. 
Methods We simultaneously measured mean flow velocity (APV) and distal coronary 
pressure (Pd) distal to a coronary stenosis, at baseline and maximal hyperemia, induced 
by adenosine. The MR was defined as the hyperemic ratio of Pd by APV. Data were 
acquired in 23 normal coronaries (group A), in 54 arteries with an intermediate stenosis 
without ischemia (group B), and rn 29 stenoses with evidence of ischemia. detected by 
non-invasive tests (group C), and in 14 arteries (group D) immediately after PCI. 
Results A significant difference was found between the MR of the different groups. The 
MR in group C was statistically higher (‘~‘0.05) compared to the other groups and the 
MR after PCI was significantly (‘p<O.O5) lower. 
Conclusion We found that the MR in areas perfused by severe coronary stenoses is ele- 
vated, suggesting that the MC can aggravate the effect of a severe coronary stenosis. 
Immediately post PCI the MR was significantly lower compared to normal arteries. 
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1202-151 Direct Vasodilatory Effects of the Antidepressant 
Sertraline in the Human Internal Mammary Artery 
Joost P. van Melle, Hendrik Buikema, Maarten P. van den Berq, Azuwerus van B&en, 
Mariolein Hensens. Wiek H. van Gilst. Thoraxcenterof the Universrtv Hosoital 
Groningen, Groningen, The Netherlands 
Background: Depression is associated with a significantly increased risk of cardiac 
events in patients who had coronary artery bypass graft (CABG) surgery. It is unknown 
whether antidepressive medication can improve cardiac prognosis in these patients. 
Because Selective Serotonin Re-uptake Inhibitors (SSRls) are frequently prescribed anti- 
depressants, we studred the vasoactive response of human Internal Mammary Artery 
(IMA) preparations to sertraline, whtch is one of the SSRls. 
Methods: IMAs (n=22) were harvested during CABG surgery and cut into rings. In 
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selected rings endothelium was rubbed. Rings were mounted in an organ bath chamber 
and prewntracted with potassium chloride. Responses of prawntraded IMA rings to 
increasing dose of sertraline (lo’-1OsMol.L~‘) were compared with vehicle. Relaxations 
were expressed as a percentage of precontraction. 
Secondly, we assessed dose-response curves of phenylephrine (10.‘-1O~sMol.L”) in the 
absence or presence of serlraline (105Mol.L~>. 
Results: Sertraline induced concentration-dependent vasodllation (p<O.Ol; repeated 
measures ANOVA combined with post-hoc t-statistics), which was profound in nature 
(maximal dilatory effects exceeding 100% in the concentration-range used). There were 
no significant differences between rubbed and unrubbed rings,, thus vasodilation was 
independent of the endothelium. Presence of sertraline markedly attenuated contractile 
responses to phenylephrine. resulting in a significant rightward shift of the concentration- 
response curve (~~0.05). 
Conclusion: Our results suggest that sertraline may be protective against arterial vasos- 
pasm in depressive post-CABG patients. Vasodilatory properties of sertraline may have 
important clinical implications in the use of SSRls. 
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1203-l 23 Hypertension Adverse Experiences Among 
Osteoarthritis Patients Treated With Rofecoxib, 
Celecoxib, or Acetaminophen in the VACT Trials 
Greoow P. Geba, Adam 8. Polis, Richard A. Petruschke, William F. Keane, Merck 8. Co., 
Inc., West Point, PA 
Background: Inhibition of cyclooxygenase (COX)-2 may alter renal function in some 
patients due to effects on renal blood flow and tubular function. We evaluated hyperten- 
sion adverse experiences (AEs) in patients treated with the COX-2 specific inhibitors, 
rofecoxib and celecoxib compared to acetaminophen. Melhods: A total of 1960 patients 
(VACT 1, N=381 and VACT 2. N=l579) with osteoarthritis of the knee were enrolled in 
two randomized. double-blind, active comparator efficacy trials. The patients received 
treatment with rofecoxib 12.5 mg (N=355) or 25 mg (N=622). celecoxib 200 mg (N=620), 
or acetaminophen 4000 mg (N=363) daily for 6 weeks. Patient demographics were simi- 
lar across treatment groups in both studies. The majority of patients were Cauoaslan 
(87%), women (68%), with a median age of 62 years. An exploratory analysis was per- 
formed to evaluate the percentage of patients with hypertension-related AEs and dlscon- 
tinuations due to hypertension-related AEs. Hypertension-related AEs were dominated 
by the term hypertension, but included all terms that implied hypertension. Results: 
Overall, 38 (1.9%) patients experienced an hypertension-related AE. The percentage of 
patients by treatment group was rofecoxib 12.5 mg, 2.8% (10 patients); rofecoxib 25 mg, 
1.3% (8 patients); celecoxib 200 mg, 1.8% (11 patients); and acetaminophen 4000 mg, 
2.5% (9 patients). The percentage for all rofecoxib patients was 1.8%. Less than 1% of 
the patients in each treatment group discontinued the studies due to a hypertension- 
related AE. No clinically meaningful difference in mean change from baseline in blood 
pressure was observed when comparing rofecoxlb at both doses to celecoxib 01 acetami- 
nophen. Conclusion: The percentage of patients with hypertension-related AEs was 
small. Although not a prespeclfied analysis, we observed comparable incidence of hyper- 
tension-related AEs comparing rofecoxlb and celecoxib. Patients treated with COX-2 
inhibitors were at no greater risk to experience a hypertension-related AE than those 
treated with acetaminophen. 
1203-124 Prevention of Renal Fibrosis With Dual ACE+NEP 
Inhibition With MDL 100,240 in a Transgenic Model of 
Angiotensin II-Dependent Hypertension 
Valeria Valdisolo, Anna Sandra Belloni. Diego Guidolin, Achille Cesare Pessina, Gian 
Paolo Rossi, Clin Med 4, Padova, Italy, University of Padua, Padova, Italy 
BACKGROUND. Dual ACE+NEP inhibition is being proposed as a novel therapeutic 
strategy in cardiovascular disease. As NEP is involved in the degradation of vasodllatory 
and growth-inhibitory peptides, like ANP. BNP, adrenomedullin and bradykinin, and is 
mainly expressed in the kidney epithelial brush border, dual ACE+NEP Inhibition might 
have peculiar nephroprotective effects. 
METHODS. To verify this hypothesis we randomly allocated male heterozygous RenP 
transgemc rat (TGR(Ren2)27), a model of prominent cardiovascular disease, to receive a 
placebo, MDL 100,240 (40 mg/Kg ) or ramipril(5 mg/Kg ) by gavage for 8 weeks. After 4 
week the bradykinin 4 receptor antagonist icatibant (0.5 mg/Kg) was administered 
(osmotic minipumps) to 50% of rats receiving MDL 100,240 or ramipril. At the end of 
treatment, glomerular density (GD), volume (GV), fibrosis (GF) and tubulointerstitial fibro- 
sis (TF) were measured by PC-assisted histomorphometry on Masson’s trichrome- and 
Sirius Red- stained cryosections with a specific software (Leica QwinTM). 
RESULTS. Compared with placebo, MDL 100,240 decreased blood pressure (from 
251+24 to 137t6 mmHg, pO.001) being as effective as ramipril (127r4). TF was signifi- 
cantly reduced (from 13tl% in placebo, m * SEM) in MDL 100,240 (to 9*1%, p=O.O03) 
and in ramipril (to 9+1%. p=O.O03) treated rats. At variance, GD, GV and GF were not 
affected. lcatibant significantly (p=O.OOl) blunted the lowenng of TF in both MDL 100,240 
(13*1%) and ramipril (13+1%) treated rats. 
CONCLUSION. 1) Enhancement of bradykinin. via 8, receptor, plays a relevant role In 
the nephroprotective effects of both MDL 100,240 and tamipril; 2) TF appear to preced 
GF. GD and GV and therefore may be an accurate index for estimating early renal dam- 
age in TGR(Ren2)27. 
1203-l 25 Effects of Valsartan and Valery1 4-Hydroxy Valsarlan on 
Human Platelets: A Possible Missing Link to Explain 
Reduction of Acute Vascular Events With Angiotensin II 
Receptor Blockers 
Victor L. Serebruany, Alex I. Malinin. David R. Lowry, David C. Sane, Randy L. Webb, 
Sidney 0. Gonlieb. Charles H. Hennekens, Sinai Hospital, Johns Hopkins University, 
Baltimore, MD, University of Miami, Miami, FL 
Background: Valsartan (V) selectively blocks angiotensin II binding to the AT, receptor. 
Since platelet activation plays a key role in the pathogenesis of coronary and cerebrovas- 
cular occlusion, and since AT, receptors are present on the platelet surface, we 
assessed the in vitro effects of V and its metabolite, valeryl 4.hydroxy valsartan (V4HV), 
on platelets in 20 subjects with multiple vascular disease risk factors. Methods: Platelet 
characteristics in blood samples pretreated and incubated with 10 nmol to 100 wmol con- 
centrations of V and V4HV were assessed by conventional and whole blood aggregome- 
try. Closure time, platelet activation units, platelet-bound fibrinogen, and platelet- 
leukocyte formation also were measured, as well as expression of platelet receptors 
using several monoclonal antibodies. Results: Pretreatment of blood with V and V4HV 
resulted in inhibition of conventional (ADP: k.0002, V; epinephrine: f=.OOOl, V4HV) 
and collagen-induced (E.02, V; P=.OOOi, V4HV) platelet aggregation. Expression of 
many monoclonal antibodies and platelet-bound fibrinogen was significantly reduced 
compared with autologous baseline activity. Closure time was delayed (E.02, V; e.03, 
4VHV), indicating platelet inhibition in whole blood under high shear conditions. Intensity 
of platelet-leukocyte formation and platelet activation remained unchanged. Platelet inhi- 
bition was not dose-dependent and was more potent for 4VHV than V in the therapeutic 
range. Conclusions: Valsartan and 4VHV exhibited significant in vitro inhibition of 
human platelets. Their antiplatelet properties appear to be independent of those of other 
antiplatelet agents. Whether valsartan reduces vascular ischemic events via additional 
pathways of platelet inhibition in patients with myocardlal infarction and ischemic stroke 
reqwes further research. 
1203-126 The Relationship Between Angiotensin Converting 
Enzyme Gene Polymorphism and Hypertensive 
Retinopathy 
Nezihi Baris, Ozer Badak, Ozgur Aslan. Onder Kirimli, Ozhan Goldeli, Bahri Akdeniz, 
Sema Guneri, Dokuz Eylul University, Izmir. Turkey 
Background: Retlnopathy is the important complication and major target organ damage 
of hypertension. We aimed to investigate the relationship between angiotensin convert- 
ing enzyme (ACE) gene polymorphism and hypertensive retmopathy. 
Methods: Fifty-one patients (31 female, mean age:53,3 r 9 years) with essential hyper- 
tension were enrolled in this study. Patients with diabetes mellitus were excluded. Hyper- 
tensive retinopathy was diagnosed in dark room with direct ophtalmoscopy by an 
ophtalmalogist blinded to climcal data. Polymerase chain reaction was used to detect the 
insertion/deletion (l/D) polymorphism of the ACE gene. Statistical analysis was per- 
formed using the chi-square and analysis of variance methods. 
Results: Basal characteristics of the patients were similar in groups. The significant dif- 
ferences were found among these groups.(Table) 
Table 
ACE Genotype 
Retinopathy DD (n=20) DI (w24) II (n=7) P 
Yes 20 (%lOO) 14 (%60,9) 2 (%28,6) <0,0001 
No 0 (%O) 9 (%39.1) 5 (%71,4) <0,0001 
Conclusion: Hypertensive patients with D allel of ACE gene represent a tendency to 
hypertensive retinopathy. Identification of ACE genotype in hypetlensive patients might 
be useful to discriminate the patients who are more susceptible to hypertensive retinopa- 
thy 
1203-l 29 Safety of the Centrally Acting Wake-Promoting Agent 
Modafinil in Hypertensive Sleep Apnea Patients 
Jonathan Sackner-Bernstein, S. Arora, Craig Q. Earl, St. Luke’s_Roosevelt Hospital 
Center, New York, NY, Cephalon Inc., West Chester, PA 
Background. Obstructive sleep apnea (OSA) IS common in patients with cardiovascular 
disease and contributes to hypertension (HTN) and sympathetic nervous system activa- 
tion. The centrally-acting wake-promoting agent modafinil reduces excessive daytime 
sleepiness (EDS) and improves quality of life (QOL) when used adjunctively in OSA. 
Because of theoretical risk of CNS stimulants in cardiovascular disease, we evaluated 
the cardiovascular effects of modafinil in OSA patients with current or past history of 
HTN. 
Methoda Effects on heart rate (HR) and systolic and diastolic blood pressure (BP) mea- 
sured at rest and clinical experiences during therapy were determined from 3 random- 
ized, double blind, placebo-controlled trials of modafinil for OSA (2-l 2 weeks of therapy 
with placebo, 200 or 400 mg qd, n=218. 109, 214 respectively). HTN was defined by cur- 
rent therapy or the diagnosis of HTN currently or in the past. 
Reeulta 274 HTN patients were middle aged (52 yrs) obese (BMl=36.3) Caucasian 
(87%) men (79%) with BP of 130/81. In HTN group, modafinil did not increase BP 01 HR, 
nor were there differences in clinical cardiovascular adverse effects. Combining HTN 
with non-HTN revealed similar lack of effect on BP and HR by modafinil 200 mg or 400 
